Xcovery Holdings, Inc.

Quick facts

Phase 3 pipeline

• X-396 (ensartinib) · Oncology
  X-396 (ensartinib) is a potent and selective inhibitor of the anaplastic lymphoma kinase (ALK) and ROS1 kinases.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Xcovery Holdings, Inc. portfolio CI brief
• Xcovery Holdings, Inc. pipeline updates RSS